Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088491 | 1.00 | PIM1 (0.35) | PIM1PIM2HRH3ADAMTS4MMP1 | |
| SCHEMBL7085826 | 0.80 | PIM1 (0.33) | PIM1PIM2HRH3ADAMTS4MMP1 | |
| SCHEMBL7090634 | 0.80 | PIM1 (0.38) | PIM1PIM2HRH3ADAMTS4MMP1 | |
| SCHEMBL7089641 | 0.80 | PIM1 (0.38) | PIM1PIM2HRH3ADAMTS4MMP1 | |
| SCHEMBL7088186 | 0.75 | PIM1 (0.34) | PIM1PIM2HRH3ADAMTS4MMP1 | |
| SCHEMBL7091719 | 0.75 | PIM1 (0.34) | PIM1PIM2HRH3ADAMTS4MMP1 | |
| SCHEMBL7085825 | 0.75 | PIM1 (0.34) | PIM1PIM2HRH3ADAMTS4MMP1 | |
| SCHEMBL7092370 | 0.74 | HRH3 (0.33) | PIM1PIM2HRH3 | |
| SCHEMBL7132800 | 0.74 | HRH3 (0.33) | PIM1PIM2HRH3 | |
| SCHEMBL7254338 | 0.67 | PIM1 (0.46) | PIM1PIM2HRH3ADAMTS4MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055084-A1 | Pharmaceutical compounds and methods of use thereof | MILLENNIUM PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003011848-A1 | BENZOHETEROCYCLES AS LIPOXYGENASE INHITIBORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055084-A1 | Pharmaceutical compounds and methods of use thereof | CYP3A5, DHPS, CYP3A43 | PIM1 944/4885PIM2 1096/4885HRH3 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.